Husein Hadeiba

Title: Husein Hadeiba: Innovator in Immunotherapy

Introduction

Husein Hadeiba is a notable inventor based in Daly City, CA (US). He has made significant contributions to the field of immunotherapy, particularly through his research on dendritic cells. His work focuses on developing methods to utilize these cells in treating various inflammatory disorders.

Latest Patents

Hadeiba holds a patent for "Tolerogenic populations of dendritic cells." This patent describes dendritic cells characterized by the expression of specific tissue-specific homing receptors, including chemokine receptors CCR9 and CMKLR1, as well as the integrin CD103. The patent outlines methods for identifying, isolating, and targeting these cells in immunotherapeutic interventions aimed at suppressing inflammatory disorders such as autoimmunity, transplantation responses, and allergic diseases. In certain embodiments, the dendritic cell populations can be fixed to render them immunosuppressive, allowing for their typing and banking for future use. Hadeiba has 1 patent to his name.

Career Highlights

Hadeiba is affiliated with Leland Stanford Junior University, where he conducts his research. His work has been instrumental in advancing the understanding of dendritic cells and their potential applications in immunotherapy.

Collaborations

Hadeiba collaborates with Eugene C Butcher, a fellow researcher in the field. Their partnership has contributed to the development of innovative approaches in immunotherapy.

Conclusion

Husein Hadeiba's contributions to the field of immunotherapy through his research on dendritic cells highlight his role as an influential inventor. His patent on tolerogenic populations of dendritic cells showcases the potential for new therapeutic strategies in treating inflammatory disorders.